Effect of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTCI Co., Ltd.
About this trial
The objective of this study is to investigate the effects of pre-meal supplementation with SugarLock® peanut skin extract and white kidney bean extract on reducing or delaying postprandial blood glucose elevation and glycemic fluctuations, and to evaluate their potential as nutritional supplements for postprandial glycemic management.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adults aged 18 years or older;
Fasting blood glucose level < 100 mg/dL;
Individuals without type 1 or type 2 diabetes.
Disqualifiers
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
Individuals with chronic gastrointestinal diseases (such as irritable bowel syndrome [IBS], inflammatory bowel disease [IBD], chronic diarrhea, celiac disease, short bowel syndrome, ulcers, colorectal cancer, etc.), a history of epilepsy or seizures, psychiatric disorders, malignant tumors, endocrine disorders, liver or kidney disease, or other major organic diseases;
Individuals with a history of gastrointestinal surgery or organ transplantation;
Individuals who have taken medications or supplements affecting blood glucose or insulin within the past three months;
Trial design
Design model
Crossover
Treatments tested in this trial
Peanut skin extract
Dietary supplementconsume two peanut skin extract capsules (200 mg/capsule) with 150 mL water
White kidney bean extract
Dietary supplementconsume two White kidney bean extract capsules (250 mg/capsule) with 150 mL water
Water
Dietary supplementconsume 150 mL water
Treatment groups
30 Participants
are divided into 3 treatment groupsGroup A: Blank controlPlacebo comparator 1 intervention
Group B: SugarLock® peanut skin extractExperimental treatment 1 intervention
Group C: White kidney bean extractActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Interstitial fluid glucose level (mg/dL)
Postprandial glucose responses will then be continuously monitored by continuous glucose monitoring system (CGM) for 3 hours
Time frame
at 3 hours after eating white riceSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov